Wilke and colleagues demonstrated that blood NfL and pNfH values could permit dynamic stage‐dependent stratification of individuals with FTD and might serve as treatment‐response biomarkers in presymptomatic FTD that help to demarcate the conversion stage. This evidence concerns the gene NEFL and frontotemporal dementia.